Attapon Cheepsattayakorn^1,2*, Ruangrong Cheepsattayakorn³ and Porntep Siriwanarangsun¹

¹Faculty of Medicine, Western University, Pathumtani Province, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10^th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

Received: March 03, 2023; Published: April 01, 2023

Currently, in cancer or lung-cancer patients, immune checkpoint inhibitors (ICIs), such as anti-CTLA-4, anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1) antibodies, etc. are widely prescribed as single agent or in combination with other anticancer-   treatment modalities [1]. Due to immune-associated adverse events (iaAEs), these ICIs can facilitate antitumor effects, such as interstitial pneumonitis, endocrine-gland-disorders-associated abnormal hormone secretion [2] that can be caused and aggravated by mRNA-based-COVID-19 vaccines (Figure 1) [1,3].

References

1. Hibino M., et al. “Safety and immunogenicity of mRNA vaccines against severe acute respiratory syndrome coronavirus 2 in patients with lung cancer receiving immune checkpoint inhibitors: a multicenter observational study in Japan”. Journal of Thoracic Oncology8 (2022): 1002-1013.
2. Brahmer JR., et al. “Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy : American Society of Clinical Oncology Clinical Practice Guideline”. Journal of Clinical Oncology 36 (2018): 1714-1768.
3. Desage AL., et al. “Vaccination and immune checkpoint inhibitors : does vaccination increase the risk of immune-related adverse events?: a systematic review of literature”. American Journal of Clinical Oncology 44 (2021): 109-113.

Citation

Citation: Attapon Cheepsattayakorn., et al. “Patients with Lung Cancer Receiving Immune Checkpoint Inhibitors: Safety and Immunogenicity of mRNA-COVID-19 Vaccination". Acta Scientific Microbiology 6.5 (2023): 01-02.

Copyright

Copyright: © 2022 Attapon Cheepsattayakorn., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.